A phase I study of toremifene
- 1 August 1990
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 16 (S1) , S27-S29
- https://doi.org/10.1007/bf01807141
Abstract
A Phase I study of the new antiestrogenic drug toremifene was carried out in 27 Japanese women, using oral doses of 10–480 mg per day for one or five days. Serum concentrations reached a dose-dependent maximum 2–6 hours after each oral administration. Side effects were generally mild.Keywords
This publication has 2 references indexed in Scilit:
- Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor modelEuropean Journal of Cancer and Clinical Oncology, 1988
- A new triphenylethylene compound, Fc-1157aCancer Chemotherapy and Pharmacology, 1986